HOME PRODUCTS COMPANY CONTACT FAQ

Research Dictionary Pharma

Sign Up FREE or Login

RFB4(dsFv)-PE38 recombinant immunotoxin

contains an anti-CD22 variable domain (Fv) fused to truncated pseudomonas exotoxin

Also Known As:

immunotoxin BL22

Networked: 7 relevant articles (2 outcomes, 0 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Pastan, Ira: 6 articles (10/2011 - 01/2005)
2.	Kreitman, Robert J: 5 articles (10/2011 - 01/2005)
3.	Onda, Masanori: 2 articles (08/2008 - 01/2005)
4.	Bogner, Christian: 1 article (01/2010)
5.	Dechow, Tobias: 1 article (01/2010)
6.	Decker, Thomas: 1 article (01/2010)
7.	Licht, Thomas: 1 article (01/2010)
8.	Lutzny, Gloria: 1 article (01/2010)
9.	Oelsner, Madlen: 1 article (01/2010)
10.	Peschel, Christian: 1 article (01/2010)

Related Diseases

1.	Hairy Cell Leukemia 07/26/2001 - "Efficacy of the anti-CD22 recombinant immunotoxin BL22 in chemotherapy-resistant hairy-cell leukemia." 09/01/2006 - "Characterization of T-cell repertoire in hairy cell leukemia patients before and after recombinant immunotoxin BL22 therapy." 01/07/2005 - "Recombinant immunotoxin BL22, containing the Fv portion of an anti-CD22 antibody, produced complete remissions in most patients with drug-resistant hairy cell leukemia but had less activity in leukemias with low CD22 expression. " 10/01/2006 - "Recombinant immunotoxin BL22 is an anti-CD22 Fv fragment fused to truncated Pseudomonas exotoxin; it induces complete remissions in a high percentage of patients with chemoresistant hairy cell leukemia. " 10/15/2011 - "Moxetumomab pasudotox is an improved, more active form of a predecessor recombinant immunotoxin, BL22 (also called CAT-3888), which produced complete remission in relapsed/refractory hairy cell leukemia (HCL), but it had a <20% response rate in chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), diseases in which the leukemic cells contain much lower numbers of CD22 target sites. "
2.	Precursor Cell Lymphoblastic Leukemia-Lymphoma (Acute Lymphoblastic Leukemia) 10/15/2011 - "Moxetumomab pasudotox is an improved, more active form of a predecessor recombinant immunotoxin, BL22 (also called CAT-3888), which produced complete remission in relapsed/refractory hairy cell leukemia (HCL), but it had a <20% response rate in chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), diseases in which the leukemic cells contain much lower numbers of CD22 target sites. "
3.	B-Cell Chronic Lymphocytic Leukemia (Chronic Lymphocytic Leukemia) 10/15/2011 - "Moxetumomab pasudotox is an improved, more active form of a predecessor recombinant immunotoxin, BL22 (also called CAT-3888), which produced complete remission in relapsed/refractory hairy cell leukemia (HCL), but it had a <20% response rate in chronic lymphocytic leukemia (CLL) and acute lymphoblastic leukemia (ALL), diseases in which the leukemic cells contain much lower numbers of CD22 target sites. "
4.	Mantle-Cell Lymphoma (Lymphoma, Mantle Cell) 01/01/2010 - "Immunotoxin BL22 induces apoptosis in mantle cell lymphoma (MCL) cells dependent on Bcl-2 expression."
5.	Neoplasms (Cancer) 08/12/2008 - "Immunotoxin BL22 targets CD22 positive malignancies and is composed of an anti-CD22 Fv fused to a 38-kDa fragment of Pseudomonas exotoxin A (PE38). "

Related Drugs and Biologics

1.	immunotoxin HA22
2.	Exotoxins
3.	Immunoglobulin Variable Region

Related Therapies and Procedures

1.	Drug Therapy (Chemotherapy)
2.	Therapeutics